Edison
Our content

Our content

Edison Sparks - Morning News

Auris Medical Holding – Interim AM-201 data

Actinogen Medical – Well-timed XanaHES study saves the day

Avacta Group – Affimer drug conjugates attracting interest

Immunicum – Full analysis of MERECA top-line results

Hutchison China MediTech – Surufatinib NETs solid data at ESMO

Hutchison China MediTech – Surufatinib NETs solid data at ESMO

Quantum Genomics – Firibastat Phase III to start by end of the year

Executive interview – RhoVac

Edison QuickView

EyeGate Pharmaceuticals – OBG pivotal study recruitment on schedule

Newron Pharmaceuticals – Xadago slows, Evenamide lags but STARS ahead

Transgene – TG4001 first efficacy data presented at ESMO

Formycon – H119 results – FYB201 FDA filing imminent

Oxford Biomedica – Investing for future growth

OSE Immunotherapeutics – R&D progress triggers milestone payment windfall

Oryzon Genomics – Interim Phase II CLEPSIDRA results at ESMO

Carmat – Half-year results and clinical updates

Browse by content type